000			nab a22 7a 4500
999			_c17344 _d17344
003			PC17344
005			20230328135954.0
008			230328b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9539 _aRuilope Urioste, Luis Miguel _eNefrología
245	0	0	_aRole of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. _h[revisión]
260			_bEuropean heart journal, _c2015
300			_a36(30):1967-73.
500			_aFormato Vancouver: Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015 Aug 7;36(30):1967-73.
501			_aPMID: 25898846
504			_aContiene 37 referencias
520			_aNeprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatatory, and anti-proliferative effects. In concert, these effects are prone to produce a powerful ventricular unloading and antihypertensive response. LCZ696 (Valsartan/sacubitril) is a first-in-class angiotensin II-receptor neprilysin inhibitor. LCZ696 is a novel drug not only for the treatment of heart failure but it is also likely to be a useful antihypertensive drug and may have a preferential effect on systolic pressure. This review discusses (i) the mechanism of action, pharmacokinetics, and pharmacodynamics of this novel drug, (ii) the efficacy, safety, and tolerability of LCZ696 in treatment of hypertension from the available trials, (iii) evidence from other contemporary trials on combined Neprilysin inhibitors, (iv) future trials and areas of research to identify hypertensive patient populations that would most benefit from LCZ696.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17344.pdf _ySolicitar documento
942			_2ddc _cREV _n0